MDACC Study No:2011-0229 ( NCT No: NCT00953420)
Title:Phase II Study of Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes in Patients with Refractory/Relapsed EBV-positive Nasopharyngeal Carcinoma (CADEN)
Principal Investigator:Bonnie S. Glisson
Treatment Agent:Carboplatin; Docetaxel; Modified T-cells
Study Status:Closed
Study Description:The goal of this clinical research study is to learn how relapsed or refractory
EBV-associated NPC tumors respond when treated with carboplatin and docetaxel
followed by EBV-specific cytotoxic T cells (EBV-CTLs). The safety and
effectiveness of study drugs will also be studied.

EBV-CTLs are a type of white blood cell. The cells are changed to recognize and
attack EBV infected cells.

Carboplatin is designed to interfere with the growth of cancer cells by
stopping cell division, which may cause the cells to die.

Docetaxel is designed to stop the growth of cancer cells, which may cause the
cells to die. It is believed to be weakly effective at killing blood vessels
in tumor tissue as well.
Hide details for General InformationGeneral Information

Disease Group:Head And Neck
Phase of Study:Phase II
Treatment Agents:Carboplatin
Modified T-cells
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Baylor College of Medicine
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Bonnie S. Glisson
Dept:Thoracic and Head and Neck Med
For Clinical Trial Enrollment:713-792-6363
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults